GPx: Funding, Investors & Team (Sep 2026)
General Prognostics (GPx) is revolutionizing remote chronic disease management with the world's first bloodless blood tests. Headquartered in Boston, MA, GPx is dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.
GPx has raised $610k across 3 funding rounds on record, the most recent an undisclosed round announced in Nov 2024.
GPx Company Profile and Key Stats
Latest funding round on record: Nov 2024.
GPx Funding Rounds
2 of 3 rounds were announced without a disclosed amount and are excluded from the total.
GPx announced an undisclosed round in Jun 2023; the amount was not disclosed.
5 months later, an undisclosed round of $610k was announced in Nov 2023.
1 years later, an undisclosed round was announced in Nov 2024 with no disclosed amount.
GPx Founders and Leadership Team
Contact details for the GPx team: 1 of 1 has an email address on file.
Start 14-day free trial →GPx Funding Compared to Other Biotechnology Startups
Funded Startups Like GPx in Biotechnology and Boston
Companies Similar to GPx
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
GPx Funding FAQs
What does GPx do?
General Prognostics (GPx) is revolutionizing remote chronic disease management with the world's first bloodless blood tests. Headquartered in Boston, MA, GPx is dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.
How much funding has GPx raised?
GPx has raised $610k across 3 rounds on record.
When did GPx last raise funding?
GPx's most recent funding round on record was announced in Nov 2024. The amount was not disclosed.
Who founded GPx?
FundedIQ lists Javier Echenique (Founder) at GPx.
Where is GPx headquartered?
GPx is based in Boston, Massachusetts, United States.
How many employees does GPx have?
GPx is in the 11-50 employee band.
About FundedIQ's GPx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GPx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.